{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-25-000069","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.820725+00:00","generated_at":"2026-05-22T17:19:58.886324+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolus refinances with $250M credit facility, cuts interest cost by 350 bps","bullets":["New $250M senior secured term loan replaces existing $125M facility; $150M drawn at closing, $100M incremental capacity available in two $50M tranches through Dec 31, 2026.","Interest rate reduced by 350 bps to SOFR + 5.00% (floor 3.50%); quarterly interest payments, bullet maturity at 5 years.","Converted from amortizing to bullet maturity; significantly reduced prepayment fees; no additional performance conditions or financial covenants for incremental tranches.","Evolus no longer required to make principal payments in 2026; refinancing enhances cash generation and financial flexibility.","Funds managed by Pharmakon Advisors, LP; Leerink Partners served as exclusive financial advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-25-000069","json":"https://secwatch.observer/filing/0001570562-25-000069.json","markdown":"https://secwatch.observer/filing/0001570562-25-000069.md","text":"https://secwatch.observer/filing/0001570562-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/0001570562-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/eols-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T17:19:58.886324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e007daac9f25a5a364e8dc95c03395cb16d3ac6","claim":"Evolus, Inc. incurred term loan of up to $250,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP at 3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t maturing 5th year anniversary of the Tranche A Closing Date.","evidence_excerpt":"the Lenders agreed to make term loans to the Company in an aggregate principal amount of up to $250,000,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/0001570562-25-000069-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"up to $250,000,000"},{"label":"Counterparty","value":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP"},{"label":"Rate","value":"3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t"},{"label":"Maturity","value":"5th year anniversary of the Tranche A Closing Date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}